First patient treated with FATE-NK100

Fate Therapeutics Inc. (Nasdaq: FATE) announced that the first patient has been treated in the DIMENSION study of FATE-NK100 to treat advanced solid tumors. Shares of the biopharmaceutical climbed $1.43 to close at $10.60.


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 

Business

Complete coverage of business news in the Twin Cities, Minnesota and elsewhere, including Fortune 500 Minnesota companies: UnitedHealth Group, Target, Best Buy, 3M, CHS, U.S. Bancorp, General Mills, C.H. Robinson, Land O’Lakes, Ecolab, Ameriprise Financial, Xcel Energy, Hormel Foods, Thrivent Financial, Polaris, Securian Financial Group, Fastenal and Patterson Cos.